Downregulation of TRMT9B and its association with clinicopathological features in thyroid cancer: an analysis of public datasets.

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL

Einstein-Sao Paulo Pub Date : 2026-10-19 eCollection Date: 2026-01-01 DOI:10.31744/einstein_journal/2026AO2165

Isadora Biazon de Souza, Larissa Mikalauskas, Felipe Yuji Koyama Azeka, Alexander de Moraes Frankiw, Nathan Mignella Greco, Maria Alice Kawashita Dalla Vecchia, Helena Panteliou Lima-Valassi, Alessandra Valéria de Sousa Faria

{"title":"Downregulation of TRMT9B and its association with clinicopathological features in thyroid cancer: an analysis of public datasets.","authors":"Isadora Biazon de Souza, Larissa Mikalauskas, Felipe Yuji Koyama Azeka, Alexander de Moraes Frankiw, Nathan Mignella Greco, Maria Alice Kawashita Dalla Vecchia, Helena Panteliou Lima-Valassi, Alessandra Valéria de Sousa Faria","doi":"10.31744/einstein_journal/2026AO2165","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the association between TRMT9B expression and clinicopathological features in thyroid carcinoma.Methods: TRMT9B mRNA expression was analyzed using The Cancer Genome Atlas Thyroid Cancer (TCGA-THCA) and Genotype-Tissue Expression (GTEx) datasets as well as six independent Gene Expression Omnibus (GEO) datasets. Protein-level data were obtained from The Human Protein Atlas. Associations between TRMT9B expression and clinicopathological parameters were evaluated in the TCGA cohort.Results: TRMT9B mRNA was significantly downregulated in thyroid tumors compared with normal tissues across multiple cohorts. In the TCGA cohort, lower TRMT9B expression was significantly correlated with advanced T stage, lymph node involvement, and aggressive histological variants of papillary thyroid carcinoma. Immunohistochemistry data qualitatively supported these findings: protein staining was lower in tumor samples than in healthy tissue.Conclusion: TRMT9B is downregulated in thyroid carcinoma and is associated with markers of disease progression. These findings suggest that TRMT9B plays a role in thyroid tumor biology. Further functional studies are required to clarify its mechanisms and potential clinical utility as a biomarker.","PeriodicalId":47359,"journal":{"name":"Einstein-Sao Paulo","volume":"24 ","pages":"eAO2165"},"PeriodicalIF":1.1000,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682766/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Einstein-Sao Paulo","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31744/einstein_journal/2026AO2165","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the association between TRMT9B expression and clinicopathological features in thyroid carcinoma.

Methods: TRMT9B mRNA expression was analyzed using The Cancer Genome Atlas Thyroid Cancer (TCGA-THCA) and Genotype-Tissue Expression (GTEx) datasets as well as six independent Gene Expression Omnibus (GEO) datasets. Protein-level data were obtained from The Human Protein Atlas. Associations between TRMT9B expression and clinicopathological parameters were evaluated in the TCGA cohort.

Results: TRMT9B mRNA was significantly downregulated in thyroid tumors compared with normal tissues across multiple cohorts. In the TCGA cohort, lower TRMT9B expression was significantly correlated with advanced T stage, lymph node involvement, and aggressive histological variants of papillary thyroid carcinoma. Immunohistochemistry data qualitatively supported these findings: protein staining was lower in tumor samples than in healthy tissue.

Conclusion: TRMT9B is downregulated in thyroid carcinoma and is associated with markers of disease progression. These findings suggest that TRMT9B plays a role in thyroid tumor biology. Further functional studies are required to clarify its mechanisms and potential clinical utility as a biomarker.

查看原文本刊更多论文

TRMT9B的下调及其与甲状腺癌临床病理特征的关系：对公开数据集的分析

目的：探讨甲状腺癌TRMT9B表达与临床病理特征的关系。方法：利用The Cancer Genome Atlas Thyroid Cancer （TCGA-THCA）和Genotype-Tissue expression （GTEx）数据集以及6个独立的Gene expression Omnibus （GEO）数据集分析TRMT9B mRNA的表达。蛋白质水平数据来自The Human Protein Atlas。在TCGA队列中评估TRMT9B表达与临床病理参数之间的关系。结果：在多个队列中，与正常组织相比，甲状腺肿瘤中TRMT9B mRNA显著下调。在TCGA队列中，较低的TRMT9B表达与晚期T分期、淋巴结累及和甲状腺乳头状癌的侵袭性组织学变异显著相关。免疫组织化学数据定性地支持这些发现：肿瘤样品中的蛋白质染色低于健康组织。结论：TRMT9B在甲状腺癌中下调，并与疾病进展标志物相关。这些发现提示TRMT9B在甲状腺肿瘤生物学中发挥作用。需要进一步的功能研究来阐明其机制和作为生物标志物的潜在临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊